Benjamin Edwards Inc. Acquires 1,457 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Benjamin Edwards Inc. grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 77.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,337 shares of the company's stock after purchasing an additional 1,457 shares during the quarter. Benjamin Edwards Inc.'s holdings in IDEXX Laboratories were worth $1,380,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. United Capital Financial Advisors LLC raised its position in shares of IDEXX Laboratories by 0.9% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after acquiring an additional 22 shares in the last quarter. Cranbrook Wealth Management LLC raised its holdings in IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after purchasing an additional 25 shares in the last quarter. Gabelli Funds LLC raised its holdings in IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after purchasing an additional 25 shares in the last quarter. Perigon Wealth Management LLC raised its holdings in IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after purchasing an additional 26 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its holdings in IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $4.19 during mid-day trading on Tuesday, reaching $505.34. The company's stock had a trading volume of 157,590 shares, compared to its average volume of 823,867. The business has a 50 day moving average price of $424.76 and a 200-day moving average price of $429.40. The firm has a market cap of $40.64 billion, a price-to-earnings ratio of 47.36, a PEG ratio of 3.41 and a beta of 1.52. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the previous year, the company earned $2.71 earnings per share. The business's revenue was up 3.6% compared to the same quarter last year. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on IDXX shares. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $524.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.